No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Fleury S.A., a Brazilian healthcare provider, along with its subsidiaries, delivers a broad spectrum of medical services. These offerings span diagnostics, various treatments, clinical analysis, health management, general medical care, orthopedics, and ophthalmology. The company organizes its operations into three primary segments: Diagnostic Medicine, Integrated Medicine, and Dental. Its service portfolio includes laboratory and imaging examinations, comprehensive diagnostic information, health check-ups, specialized reference laboratory functions, genomic testing, day clinic facilities, infusion centers, and dental imaging and radiology. Additionally, Fleury provides Saúde I, a digital health platform that facilitates teleconsultations, remote medical advice, online diagnostic exams, and virtual procedures. It further extends its services to corporate clients with tailored solutions, offers in-person primary care, and supports medical professionals through digital office tools and ongoing medical education. Established in 1926 and headquartered in São Paulo, Brazil, the company operates an extensive network comprising 284 outpatient service centers and 31 hospital-based units, many of which are known under brands like Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, Diagmax, IRN / CPC, Diagnosis a+, a+BA, Pretti, and Bioclinic.

• Guangzhou Kingmed Diagnostics Group Co., Ltd.
• Vimian Group AB (publ)
• Dian Diagnostics Group Co.,Ltd.
• Personalis, Inc.
• Vijaya Diagnostic Centre Limited
• Genetic Technologies Limited
• BGI Genomics Co., Ltd.
• Metropolis Healthcare Limited